GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

As Ozempic use rises, some patients report unexpected nasal symptoms, prompting researchers to investigate this new and unusual side effect.

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy, gestational diabetes, have a preterm birth or cesarean ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

Hair loss was not a reported side effect of Mounjaro, but it was reported with other GLP-1 agonists. Mounjaro can cause side effects, such as nausea, vomiting, and diarrhea. But, hair loss was not ...

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.